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To assess invasive pneumococcal disease (IPD) clinical presentations and relationships with age and
serotype in hospitalized children (<15 years) after PCV7 implementation in Madrid, Spain, a prospective
2-year (May 2007 to April 2009) laboratory-confirmed (culture and/or PCR) IPD surveillance study was
performed (22 hospitals). All isolates (for serotyping) and culture-negative pleural/cerebrospinal fluids
were sent to the reference laboratory for pneumolysin (ply) and autolysin (lyt) gene PCR analysis. A total
of 330 IPDs were identified: 263 (79.7%) confirmed by culture and 67 (20.3%) confirmed by PCR. IPD
distribution by age (months) was as follows: 23.6% (<12), 15.8% (12 to 23), 15.5% (24 to 35), 22.4% (36
to 59), and 22.7% (>59). Distribution by clinical presentation was as follows: 34.5% bacteremic pneumo-
nia, 30.3% pediatric parapneumonic empyema (PPE), 13.6% meningitis, 13.3% primary bacteremia, and
8.2% others. Meningitis and primary bacteremia were the most frequent IPDs in children <12 months old,
and bacteremic pneumonia and PPE were most frequent in those >36 months old. Frequencies of
IPD-associated serotypes were as follows: 1, 26.1%; 19A, 18.8%; 5, 15.5%; 7F, 8.5%; 3, 3.9%; nontypeable/
other 30 serotypes, 27.3%. Serotype 1 was linked to respiratory-associated IPD (38.6% in bacteremic
pneumonia and 38.0% in PPE) and children of >36 months (51.4% for 36 to 59 months and 40.0% for >59
months), while serotype 19A was linked to nonrespiratory IPDs (31.1% in meningitis, 27.3% in primary
bacteremia, and 51.9% in others) and children of <24 months (35.9% for children of <12 months and
36.5% for those 12 to 23 months old), with high nonsusceptibility rates for penicillin, cefotaxime, and
erythromycin. After PCV7 implementation, non-PCV7 serotypes caused 95.5% of IPDs. The new 13-valent
conjugate vaccine would provide 79.1% coverage of serotypes responsible for IPDs in this series.
Invasive pneumococcal disease (IPD) remains a leading
cause of serious illness in children and adults. After the intro-
duction of the 7-valent pneumococcal conjugate vaccine
(PCV7) into childhood vaccination calendars, rates of IPD
caused by the seven serotypes covered by the vaccine (4, 6B,
9V, 14, 18C, 19F, and 23F) have decreased substantially not
only among vaccinated children but also among unvaccinated
children and adults as a result of the reduced nasopharyngeal
carriage of pneumococcus in vaccinated children and the re-
duced transmission to unvaccinated populations (3, 5). In ad-
dition, an increase in the incidence of IPD caused by non-
PCV7 serotypes has been observed (4, 21) with an increase in
penicillin nonsusceptibility (9, 10), mainly due to serotype 19A
(11, 18, 20). Postlicensure monitoring of IPD is important to
track potential changes in the IPD disease burden caused by
nonvaccine serotypes, since IPD varies widely depending on
such factors as geographical area, age, race, and site of infec-
tion (16).
PCV7 has been available in Spain since October 2001 but
only in the private market for healthy children. Use of the
vaccine has increased from 2002 onwards, with reported vac-
cine coverage in 2006 below 50%, assuming complete vaccina-
tion schedules (13). Selective PCV7 vaccination has resulted in
a low impact in the incidence of IPD in children in Spain (2,
21) given the intermediate vaccination coverage achieved and
the increase in disease detection that has occurred over that
time (22). In October 2006, the Autonomous Region of Ma-
drid approved its inclusion in the childhood vaccination calen-
dar, carrying out necessary clinical and serotype surveillances
to update IPD changes with universal pediatric vaccination.
The aim of this study was to assess clinical presentations and
their relation to age and serotype distribution in children hos-
pitalized due to IPD after the introduction of PCV7 in the
childhood vaccination calendar in Madrid.
* Corresponding author. Mailing address: Microbiology Depart-
ment, Hospital Clínico San Carlos, c/ Martín Lagos s/n, 28040 Madrid,
Spain. Phone: 34 91 3303486. Fax: 34 91 3303478. E-mail: jpicazo
@microb.net.
 Published ahead of print on 3 November 2010.
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MATERIALS AND METHODS
A prospective, 2-year (1st period, May 2007 to April 2008; 2nd period, May
2008 to April 2009), hospital-based IPD surveillance study was carried out in all
hospitals (20 centers in the 1st period, two new centers added in the 2nd one)
with a pediatric department located in the Autonomous Region of Madrid
(approximately 6 million inhabitants) in Spain. The study population consisted in
hospitalized children (15 years old) with IPD laboratory confirmed by culture
and/or PCR. IPD was defined as the presence of Streptococcus pneumoniae in
normal sterile fluids, such as blood, pleural fluid, and cerebrospinal fluid. Basic
demographic data (age, gender, underlying conditions, and PCV7 vaccination
status), clinical presentation, length of hospital stay, admission to an intensive
care unit (ICU), and outcome were recorded. Local research ethics committees
approved the study protocol.
Samples were sent to the clinical microbiology laboratory at each center for
microbiological culture and/or PCR detection. All pneumococcal isolates were
sent to a single reference laboratory (Microbiology Department of the Univer-
sitary Clinic Hospital in Madrid) for serotyping by Quellung reaction and sus-
ceptibility determination. Pleural and cerebrospinal fluids not yielding positive
culture were also sent to the reference laboratory to be analyzed by pneumolysin
(ply) and autolysin (lyt) gene PCR (8, 27). Pneumococci confirmed by PCR were
serotyped using a real-time PCR assay (26). Susceptibilities to penicillin, amoxi-
cillin, cefotaxime, erythromycin, and levofloxacin were determined by micro-
dilution following CLSI recommendations (6). Current CLSI breakpoints (7)
were considered for susceptibility interpretation. Isolates with intermediate or
high-level resistance were defined as nonsusceptible. Molecular typing of the
isolates was performed by using the DiversiLab system (bioMerieux, Marcy-
l’Etoile, France), a semiautomatized repetitive element sequence-based PCR
(rep-PCR) (28); isolates that showed 95% similarity were considered part of
the same cluster.
RESULTS
During the study period, 330 cases of IPD were identified
(163 cases from May 2007 to April 2008 and 167 cases from
May 2008 to April 2009): 263 (79.7%) cases were confirmed by
culture yielding growth of S. pneumoniae, and 67 (20.3%) were
confirmed by PCR identification in pleural or cerebrospinal
fluids. Seventy-eight (23.6%) children were 12 months old,
52 (15.8%) were 12 to 23 months old, 51 (15.5%) were 24 to 35
months old, 74 (22.4%) were 36 to 59 months old, and 75
(22.7%) were 59 months old. The most frequent underlying
medical conditions were asthma (n  36; 10.9%), prematurity
(n  29; 8.8%) and immunodeficiency (n  10; 3.0%). A total
of 21 children (6.4%) had been admitted to hospital within the
previous 3 months, and 87 out of 330 (26.4%) had received
antibiotics in the preceding month.
The distribution of cases by clinical presentation was as
follows: bacteremic pneumonia, n  114 (34.5%); pediatric
parapneumonic empyema (PPE), n  100 (30.3%); meningitis,
n  45 (13.6%); primary bacteremia, n  44 (13.3%); others,
n  27 (8.2%) (bacteremia secondary to otitis, acute mastoid-
itis, peritonitis, or cerebral or pulmonary abscess). Figure 1
shows clinical presentations of IPD by age group. The highest
rates of IPD were found in children aged 12 months or 36
months, with meningitis and primary bacteremia as the most
frequent IPDs in children 12 months old and bacteremic
pneumonia and PPE in those 36 months old. The profile of
IPD in children 12 months old was also markedly different
from the profiles of other clinical presentations, since bactere-
mic pneumonia and PPE were also the two most frequent
clinical presentations in the remaining study age groups.
Table 1 shows demographic and clinical data by clinical
presentation of IPD. Children presenting meningitis and pri-
mary bacteremia (median, 7.0 months for both) were younger
than those presenting bacteremic pneumonia or PPE (median,
47.0 and 40.5 months, respectively). Median days of hospital-
ization and percentages of ICU admission were higher in chil-
dren with meningitis (15.0 days and 75.6%, respectively) and
PPE (17.0 days and 71.0%, respectively) than in those present-
ing bacteremia: bacteremic pneumonia (7.0 days and 14.9%,
respectively) or primary bacteremia (7.0 days and 9.1%, re-
spectively). Meningitis and PPE presented the lowest rates of
cure without sequelae (77.8% and 88.0%, respectively, versus
95.6% and 100% for bacteremic pneumonia and primary bac-
teremia, respectively). Mortality was 0.9% in total but was
clustered in children presenting meningitis (6.7% mortality).
Serotypes associated with the 330 IPD cases of the present
study were serotypes 1 (86 cases; 26.1%), 19A (62 cases,
18.8%), 5 (51 cases, 15.5%), 7F (28 cases, 8.5%), and 3 (13
cases, 3.9%), and nontypeable pneumococci or 30 other sero-
types (90 cases, 27.3%). Table 2 shows detailed percentages of
serotypes by study period. Figure 2 shows the distribution of
FIG. 1. Per-age distribution of clinical presentations (%) of invasive disease: bacteremic pneumonia (dotted bars), parapneumonic pleural
effusion (white bars), meningitis (grey bars), primary bacteremia (diagonal stripe bars), and others (black bars).
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serotypes by age group. Inverse figures for serotypes 1 and 19A
can be seen by comparing figures in children 24 months and
36 months of age: serotype 19A was the most frequently
isolated in children 24 months of age (35.9% for children
12 months old and 36.5% for those 12 to 23 months old),
with rates for serotype 1 of 3.8% (12 months) and 13.5% (12
to 23 months), in contrast to low rates of serotype 19A in
children aged 36 months (4.1% for 36 to 59 months and 8.0%
for 59 months), with serotype 1 being the most frequent
(51.4% for 36 to 59 months and 40.0% for 59 months) in this
age group.
Table 3 shows serotype distribution by clinical presentation.
Serotype 1 was linked to respiratory-associated IPD (38.6%
and 38.0% in bacteremic pneumonia and PPE, respectively),
with lower rates of serotype 19A (9.6% and 11.0%, respec-
tively). On the contrary, serotype 19A was linked to IPDs with
origins other than the respiratory tract (31.1% in meningitis,
27.3% in primary bacteremia, and 51.9% in other IPDs), with
low rates of serotype 1 (0.0%, 4.5%, and 7.4%, respectively).
Of the 330 children included, PCV7 vaccination status was
known for 328. Of them, 105 (32.0%) had not received any
PCV7 dose and 223 (68.0%) had received at least one PCV7
dose (30.5% had received four doses, 39.0% three doses,
16.1% two doses, 12.1% one dose, and 2.2% an unknown
number of doses). Among the 15 children that were infected by
serotypes included in PCV7, four had received at least one
PCV7 dose: a 28-month-old child (which had received one
dose) and a 15-month-old child (which had received three
doses) presenting PPE caused by serotype 14, a 2-month-old
child (which had received one dose) presenting primary bac-
teremia caused by serotype 19F, and one 21-month-old child
(which had been vaccinated with four doses) with other IPD
presentation due to serotype 19F.
Of the 263 pneumococci isolated, 262 were recovered for
susceptibility at the reference laboratory. Table 4 shows sus-
ceptibility data. Overall nonsusceptibility rates for parenteral
penicillin, cefotaxime, and erythromycin were 16.8%, 12.2%,
and 27.9%, respectively. Nonsusceptibility was clustered
mainly in serotype 19A, with nonsusceptibility rates of 50.9%,
49.1%, and 92.5%, respectively. When the subgroup of 42
meningitis isolates was considered, 23 (54.8%) and 13 (31.0%)
were nonsusceptible to penicillin and cefotaxime, respectively.
The only serotype with enough isolates (among those from
meningitis) for study of susceptibility was serotype 19A (13
isolates), with nonsusceptibility rates of 92.3% and 84.6% for
TABLE 1. Demographic and clinical data by clinical presentation of invasive disease
Characteristic
Value for clinical presentationa
Total BP PPE M PB Other
Total subjects 330 114 100 45 44 27
% male 55.8 57.0 51.0 57.8 61.4 55.6
Age, mo median (interquartile range) 31.0 (12.0, 56.0) 47.0 (30.0, 63.0) 40.5 (26.0, 60.5) 7.0 (5.0, 27.0) 7.0 (2.0, 17.0) 11.0 (9.0, 31.0)
No. of days in hospital median
(interquartile range)
12.0 (6.0, 17.0) 7.0 (5.0, 12.0) 17.0 (14.0, 21.0) 15.0 (13.0, 21.0) 7.0 (5.0, 10.0) 8.0 (6.0, 13.0)
No. (%) with ICU admission 131 (39.7) 17 (14.9) 71 (71.0) 34 (75.6) 4 (9.1) 5 (18.5)
No. of days in ICU median
(interquartile range)
4.0 (2.0, 7.0) 5.0 (2.0, 13.0) 4.0 (1.0, 7.0) 4.0 (3.0, 10.0) 2.5 (1.5, 4.0) 3.0 (1.0, 6.0)
Outcome (%)
Mortality 0.9 0.0 0.0 6.7 0.0 0.0
Cure with sequelae 7.3 4.4 12.0 15.6 0.0 0.0
Cure without sequelae 91.8 95.6 88.0 77.8 100 100
a BP, bacteremic pneumonia; PPE, parapneumonic pleural effusion; M, meningitis; PB, primary bacteremia.
TABLE 2. Serotype distribution by surveillance period
Serotype
No. (%) of isolatesa
Total 1st period 2nd period
1 86 (26.1) 36 (22.9) 50 (29.9)
19A 62 (18.8) 23 (14.6) 39 (23.4)
5 51 (15.5) 34 (21.7) 17 (10.2)
7F 28 (8.5) 14 (8.9) 14 (8.4)
3 13 (3.9) 5 (3.2) 8 (4.8)
14 6 (1.8) 3 (1.9) 3 (1.8)
15B 6 (1.8) 3 (1.9) 3 (1.8)
19F 6 (1.8) 4 (2.5) 2 (1.2)
12F 5 (1.5) 1 (0.6) 4 (2.4)
24F 5 (1.5) 3 (1.9) 2 (1.2)
6A 4 (1.2) 4 (2.5) 0
11A 4 (1.2) 2 (1.3) 2 (1.2)
10A 3 (0.9) 0 3 (1.8)
23B 3 (0.9) 1 (0.6) 2 (1.2)
35B 3 (0.9) 1 (0.6) 2 (1.2)
Serogroup 6 2 (0.6) 0 2 (1.2)
6C 2 (0.6) 0 2 (1.2)
8 2 (0.6) 2 (1.3) 0
15A 2 (0.6) 1 (0.6) 1 (0.6)
15C 2 (0.6) 1 (0.6) 1 (0.6)
17F 2 (0.6) 2 (1.3) 0
21 2 (0.6) 2 (1.3) 0
22F 2 (0.6) 1 (0.6) 1 (0.6)
6B 1 (0.3) 0 1 (0.6)
9V 1 (0.3) 1 (0.6) 0
11F 1 (0.3) 1 (0.6) 0
13 1 (0.3) 0 1 (0.6)
23F 1 (0.3) 1 (0.6) 0
24B 1 (0.3) 1 (0.6) 0
25A 1 (0.3) 0 1 (0.6)
33A 1 (0.3) 0 1 (0.6)
33B 1 (0.3) 0 1 (0.6)
33F 1 (0.3) 0 1 (0.6)
35F 1 (0.3) 1 (0.6) 0
41F 1 (0.3) 1 (0.6) 0
Other/nontypeable 17 (5.2) 14 (8.6) 3 (1.8)
a First period, May 2007 to April 2008; second period, May 2008 to April 2009;
total, May 2007 to April 2009. In total, 330 isolates were analyzed. For the 1st
period, n  163; for the 2nd period, n  167.
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penicillin and cefotaxime, respectively, applying CLSI break-
points for meningitis.
Genotyping showed that 91% of serotype 1 isolates pre-
sented a monoclonal pattern (pattern 6, with the 6a and 6b
variants) and serotype 19A presented a polyclonal pattern
(44.8% for pattern 20, 36.2% for pattern 23, 6.9% for patterns
21 and 24, 3.4% for pattern 25, and 1.7% for pattern 22). In
serotype 5, 51% of isolates presented pattern 1 and 41.5%
presented pattern 3, and in serotype 7F, 70% of isolates cor-
responded to pattern 17 (and its 17c variant) and 30% to
pattern 19.
DISCUSSION
Geographic and age-related differences in the incidences of
certain serotypes have led to the proposal that each serotype
can be considered a different pathogen from an epidemiolog-
ical perspective (23). In the pre-PCV7 era, it was proposed that
some serotypes have a propensity to invade one clinical site
rather than another and may therefore be disproportionately
responsible for certain IPD manifestations (1, 24). Serotype
distribution is related to age and IPD clinical manifestations,
and all these factors determine outcome (14, 19). In this sense,
in the prevaccine era, those serotypes included in PCV7 were
found less often in older children than in younger ones, and
serotypes 1 and 14 were more often isolated from blood and
serogroups 6, 10, and 23 from cerebrospinal fluid (15).
Changes in the distribution of serotypes may be associated with
changes in clinical types of IPD (15).
In Spain, the estimated coverage of PCV7 in the prevaccine
era was 78% based on all pneumococcal strains isolated from
children of ages 0 to 14 years received at the Spanish Refer-
ence Pneumococcal Laboratory on a voluntary basis (12). Ac-
cording to this passive nationwide surveillance system, the in-
troduction of this vaccine in 2001 produced a significant
decrease in IPD incidence due to PCV7 serotypes, while the
incidence of non-PCV7 serotypes (mainly serotypes 1 and
19A) increased, with the consequence that there was no clear
pattern in the overall incidence of IPD (11, 21).
In contrast to other studies analyzing data from other re-
gions through passive surveillance systems or based on a small
number of involved hospitals, data of the present study were
obtained through a hospital-based IPD active surveillance in
all hospitals with pediatric departments located in the Auton-
omous Region of Madrid, the only region in Spain that has
included PCV7 in the childhood vaccination calendar, thus
exploring relationships between age, serotypes, and clinical
presentations in this setting.
In the present study, respiratory-associated IPDs (bacter-
emic pneumonia and PPE) were the most frequent in the
pediatric population analyzed, as previously described (25).
However, when children were analyzed by age group, children
12 months old presented a different IPD pattern, with high
rates of meningitis and primary bacteremia and low rates of
FIG. 2. Per-age distribution of serotypes (%) causing invasive disease: serotype 1 (horizontal stripe bars), serotype 19A (dotted bars), serotype
5 (diagonal stripe bar), serotype 7F (grey bars), serotype 3 (black bars), and other serotypes (white bars).
TABLE 3. Serotype distribution by clinical presentation
Serotype
No. (%) of isolatesa
BP PPE M PB Other Total
1 44 (38.6) 38 (38.0) 0 (0.0) 2 (4.5) 2 (7.4) 86 (26.1)
19A 11 (9.6) 11 (11.0) 14 (31.1) 12 (27.3) 14 (51.9) 62 (18.8)
5 24 (21.1) 15 (15.0) 3 (6.7) 6 (13.6) 3 (11.1) 51 (15.5)
7F 8 (7.0) 9 (9.0) 3 (6.7) 8 (18.2) 0 (0.0) 28 (8.5)
3 2 (1.8) 8 (8.0) 1 (2.2) 1 (2.3) 1 (3.7) 13 (3.9)
Other 25 (21.9) 19 (19.0) 24 (53.3) 15 (34.0) 7 (25.9) 90 (27.3)
a BP, bacteremic pneumonia (n  114); PPE, parapneumonic pleural effusion (n  100); M, meningitis (n  45); PB, primary bacteremia (n  44). For “Other,”
n  27. In total, 330 isolates were analyzed.
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respiratory-associated IPDs, and for children 24 months old,
clinical presentations were, in the majority of cases, respirato-
ry-associated IPDs.
The most common IPD isolates in the present study be-
longed to serotypes 1, 19A, 5, 7F, and 3, results similar to those
from a pooled analysis of publications with data from eight
European countries after PCV7 introduction (17). In respira-
tory-associated IPDs, serotype 1 (with a monoclonal pattern
fully susceptible to penicillin and cefotaxime) was the most
prevalent (38.3%), with 18.2% of cases caused by serotype 5
(fully susceptible) and 10.3% by serotype 19A (with a poly-
clonal pattern showing nonsusceptibility rates of 50.9%, 49.1%,
and 92.5% for penicillin, cefotaxime, and erythromycin, re-
spectively). Serotype 19A was the most prevalent (34.5%) in
non-respiratory-associated IPDs (meningitis, primary bactere-
mia, and other), with low rates for serotype 1 (3.4% of cases).
The strong associations between clinical manifestations and
pneumococcal serotype have relevant implications for the
treatment of IPD in Madrid. In this respect, pulmonary forms
of IPD, both bacteriemic pneumonia and PPE, caused mostly
by serotypes 1 and 5, can be effectively treated with penicillin
or ampicillin, whereas the high nonsusceptibility rates for
cefotaxime of serotype 19A make association with other anti-
biotics necessary.
Considering the described IPD by age group and serotype
rate, it was not surprising to find that serotype 19A was the
most frequently isolated (36.2% cases) in younger children
(24 months of age), with a low frequency of isolation of
serotype 1 (7.7%), which was the most frequently isolated in
children older than 36 months (45.6% cases), with low rates of
serotype 19A (6.0%).
In the present study, only 15 (4.5%) IPD cases were caused
by PCV7 serotypes, and of them, 11 occurred in children that
had not received PCV7. This means that 95.5% of IPDs were
caused by non-PCV7 serotypes, indicating the need for enlarg-
ing pneumococcal coverage with a vaccine, including mainly
serotypes 1 and 19A, which were the most frequent in this
series. The new 13-valent conjugate vaccine, including the se-
rotypes most frequent in this study (1, 19A, 5, 7F, and 3) plus
serotype 6A (only 4 isolates out of 330; 1.2%), would provide
79.1% coverage of serotypes responsible for IPDs in this series:
75.6% in children 12 months old, 82.7% in those 12 to 23
months old, 68.6% in those 24 to 35 months old, 82.4% in
those 36 to 59 months old, and 84.0% in children 59 months
old. By clinical presentation, the 13-valent vaccine would cover
84.2% of the serotypes responsible for bacteremic pneumonia,
84.0% of those responsible for PPE, and 75.0% of those re-
sponsible for primary bacteremia but 57.8% of those respon-
sible for meningitis.
Due to evolving epidemiology, the 13-valent conjugate vac-
cine offers clear benefits as a preventive measure against IPD
in children, both from the age and IPD clinical presentation
perspectives. Clinical and serotype surveillances are warranted
following vaccine introduction to keep updated on the chang-
ing relationship between serotypes and the burden of IPD.
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